Recent Updates
Recently added Catalysts

AZD6234

Phase 2

Endocrinology | Small molecule | Metabolic |AstraZeneca PLC|Last Updated: Mar 3, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment69
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06851858Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor AgonistPHASE2 ACTIVE NOT_RECRUITING 69 — — Mar 12, 2025May 27, 2026Mar 3, 202618 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percent change in body weight from baseline at Study Week 26
From baseline to week 26

To determine whether treatment with AZD6234 is superior to placebo for weight loss at Study Week 26

Weight loss ≥ 5% from baseline at Study Week 26
From baseline to week 26

To assess the effect of AZD6234 versus placebo on the proportion of participants with weight loss ≥ 5% from baseline at Study Week 26

Secondary Endpoints
Weight loss ≥ 10% from baseline at Study Week 26
From baseline to week 26
Absolute change in body weight (kg) from baseline at Study Week 26
From baseline to week 26
Change in HbA1c from baseline at Study Week 26.
From baseline to week 26
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AZD6234EXPERIMENTALWeekly SC injections of AZD6234
Placebo for AZD6234PLACEBO_COMPARATORWeekly SC injections of matching placebo
Interventions
NameTypeDescription
AZD6234DRUGWeekly SC injections of AZD6234
Placebo to matchDRUGWeekly SC injections of matching placebo
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersYes
Study Sites18

Inclusion Criteria: 1. Be 18 to 75 years old at the time of signing the informed consent. 2. Diagnosed with type 2 diabetes ≥ 180 days before screening. 3. HbA1c value at screening of ≥ 6.0% (42 mmol/mol) and ≤ 10% (86 mmol/mol). 4. On a stable maintenance dose of an injectable GLP-1 RA. 5. At Scre...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06851858primaryCompletionDate: changed
LOWMay 24, 2026NCT06851858studyFirstPostDate: changed